Sirolimus- versus paclitaxel-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials.

Primary percutaneous coronary intervention (PCI) is the standard of care in patients with acute ST-segment elevation myocardial infarction (STEMI), since it is associated with a mortality reduction as compared with thrombolytic therapy alone. At this regard, we have previously demonstrated that drug-eluting stents are more effective than bare-metal stents in reducing the need for repeat revascularization of target vessel, without safety concerns [1] and [2]. However, it is unclear whether there are differences in clinical outcomes between sirolimus- (SES) and paclitaxel-eluting stent (PES). Herein, we report a meta-analysis of randomized studies comparing SES versus PES in patients undergoing primary PCI.